News

CF-370, an expeimental therapy by ContraFect, reduces the number of hard-to-treat Pseudomonas aeruginosa bacteria in a rabbit model of pneumonia, an infection that inflames the lungs. P. aeruginosa, the most common cause of lung infections in people with cystic fibrosis (CF), can evade the body’s immune…

Patients, family, friends, and caregivers will come together this May for Cystic Fibrosis (CF) Awareness Month to educate the public about the condition and raise money for research and care. A number of CF organizations have events planned throughout the month, including the largest U.S.-based nonprofit, the Cystic Fibrosis…

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…

Inspired by a cousin who lives with cystic fibrosis (CF), a University of Central Florida (UCF) undergraduate student will use a $4,000 Cystic Fibrosis Foundation (CFF) grant to seek better treatments for the genetic disease that affects the lungs and other organs. The young researcher, Sahiba Ahmed,…

A lung and pancreatic cell transplant from a single donor to people with end-stage cystic fibrosis (CF) and CF-related diabetes (CFRD) safely and effectively improved their lung function, metabolic control, and quality of life, data from a small Phase 1/2 trial show. Given that CFRD increases the risk of complications…

Adults with cystic fibrosis (CF) have significantly higher levels of anti-inflammatory oxylipins — a type of fatty molecule — and lower levels of pro-inflammatory fatty molecules in their saliva relative to healthy individuals, a study shows. This suggests a shift toward an anti-inflammatory response in the fatty molecule profile…

A noninvasive measure of lung function called lung clearance index (LCI) could be used to identify children and adolescents with cystic fibrosis (CF) who are at higher risk of a pulmonary exacerbation, an Italian study found. Notably, this work involved patients with normal or mildly reduced forced expiratory volume…

Health Canada has expanded the approval of Vertex Pharmaceuticals‘ triple-combination modulator treatment Trikafta to cover children with cystic fibrosis (CF) as young as 6 who have at least one copy of the F508del mutation. Trikafta had been approved only for patients ages 12 and older in Canada. According to…

A fungus called Aspergillus fumigatus can significantly affect lung function and structure, as well as increase the number of pulmonary exacerbations — episodes of a sudden worsening of respiratory symptoms — in children with cystic fibrosis (CF), a study suggests. The findings shed light on the need for early…

Sionna Therapeutics, a life sciences company that is developing a pipeline of experimental treatments for cystic fibrosis (CF), has announced its official launch following the closing of a $111 million Series B financing. The company is aiming to treat the underlying cause of CF. “Our mission at Sionna is…